We are conducting the ELiSA Study (Evaluation of Lixivaptan In Subjects with ADPKD), a Phase 2 clinical trial that will evaluate the safety, pharmacokinetics and pharmacodynamics of multiple doses of lixivaptan in patients with ADPKD with relatively preserved kidney function (chronic kidney disease stages CKD1 and CKD2) and moderately impaired renal function (CKD3).

Study participants will take lixivaptan by mouth twice a day for 7 days and will need to be able to stay overnight at a clinical research unit.

The study is currently enrolling and is expected to include up to 35 patients at 15 US sites.

You may be able to take part in the ELiSA Study if you:

  • Have been diagnosed with ADPKD
  • Are 18 to 60 years of age
  • Have chronic kidney disease in stage CKD1, CKD2, or CKD3

 

 

For more information about the ELiSA study, please visit the study record at the Clinicaltrials.gov website at this link.